Changes in Serum Metabolomics in Idiopathic Pulmonary Fibrosis and effect of approved antifibrotic medication
B. Seeliger (Hannover, Germany), A. Carleo (Hannover, Germany), P. Wendel-Garcia (Zurich, Switzerland), J. Fuge (Hannover, Germany), A. Worboys (Barcelona, Spain), S. Schuchardt (Hannover, Germany), M. Molina-Molina (Barcelona, Spain), A. Prasse (Hannover, Germany)
Source: International Congress 2022 – Promising new approaches in idiopathic interstitial pneumonias
 
Rating: 
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
B. Seeliger (Hannover, Germany), A. Carleo (Hannover, Germany), P. Wendel-Garcia (Zurich, Switzerland), J. Fuge (Hannover, Germany), A. Worboys (Barcelona, Spain), S. Schuchardt (Hannover, Germany), M. Molina-Molina (Barcelona, Spain), A. Prasse (Hannover, Germany). Changes in Serum Metabolomics in Idiopathic Pulmonary Fibrosis and effect of approved antifibrotic medication. 1944
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
|
|